Ultragenyx Pharmaceutical Inc. (RARE)
Largest Insider Buys in Sector
RARE Stock Price History Chart
RARE Stock Performance
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Insider Activity of Ultragenyx Pharmaceutical Inc.
Over the last 12 months, insiders at Ultragenyx Pharmaceutical Inc. have bought $0 and sold $8.63M worth of Ultragenyx Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at Ultragenyx Pharmaceutical Inc. have bought $218,150 and sold $12.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $218,150 was made by KAKKIS EMIL D (President & CEO) on 2019‑09‑11.
List of Insider Buy and Sell Transactions, Ultragenyx Pharmaceutical Inc.
| 2024-06-12 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 9,806 0.0128% | $45.00 | $441,270 | -11.49% | |
| 2024-06-10 | Sale | Sanders Corazon (Corsee) D. | director | 1,737 0.002% | $41.10 | $71,391 | -5.41% | |
| 2024-05-02 | Sale | Crombez Eric | EVP and Chief Medical Officer | 354 0.0004% | $43.66 | $15,456 | -5.03% | |
| 2024-04-18 | Sale | Crombez Eric | EVP and Chief Medical Officer | 142 0.0002% | $44.10 | $6,262 | -4.54% | |
| 2024-03-11 | Sale | Kassberg Thomas Richard | CBO & EVP | 11,509 0.0144% | $49.93 | $574,644 | -11.53% | |
| 2024-03-07 | Sale | Fust Matthew K | director | 12,195 0.0147% | $50.88 | $620,443 | -15.34% | |
| 2024-03-01 | Sale | Kassberg Thomas Richard | CBO & EVP | 1,011 0.0012% | $53.76 | $54,351 | -19.54% | |
| 2024-03-01 | Sale | Pinion John Richard | See Remarks | 4,173 0.0051% | $53.76 | $224,340 | -19.54% | |
| 2024-03-01 | Sale | Parschauer Karah Herdman | EVP and Chief Legal Officer | 3,756 0.0046% | $53.76 | $201,923 | -19.54% | |
| 2024-03-01 | Sale | Harris Erik | EVP & Chief Commercial Officer | 4,768 0.0058% | $53.76 | $256,328 | -19.54% | |
| 2024-03-01 | Sale | Crombez Eric | EVP and Chief Medical Officer | 1,238 0.0015% | $53.76 | $66,555 | -19.54% | |
| 2024-03-01 | Sale | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 341 0.0004% | $53.76 | $18,332 | -19.54% | |
| 2024-02-07 | Sale | KAKKIS EMIL D | President & CEO | 30,000 0.0366% | $45.00 | $1.35M | -1.05% | |
| 2023-12-29 | Sale | KAKKIS EMIL D | President & CEO | 30,000 0.0365% | $47.87 | $1.44M | -6.48% | |
| 2023-10-23 | Sale | Kassberg Thomas Richard | CBO & EVP | 39,878 0.057% | $32.78 | $1.31M | +37.50% | |
| 2023-10-19 | Sale | KAKKIS EMIL D | President & CEO | 47,853 0.0673% | $33.52 | $1.6M | +31.29% | |
| 2023-09-07 | Sale | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 2,163 0.003% | $40.80 | $88,249 | +3.50% | |
| 2023-09-05 | Sale | Harris Erik | EVP & Chief Commercial Officer | 6,000 0.0084% | $37.96 | $227,760 | +11.66% | |
| 2023-09-01 | Sale | Huizenga Theodore Alan | SVP, Chief Accounting Officer | 970 0.0013% | $37.15 | $36,032 | +12.15% | |
| 2023-06-30 | Sale | Sanders Corazon (Corsee) D. | director | 585 0.0008% | $46.76 | $27,355 | -9.03% |
Insider Historical Profitability
| KAKKIS EMIL D | President & CEO | 539770 0.6573% | $40.53 | 2 | 21 | +13.31% |
| Kassberg Thomas Richard | CBO & EVP | 252823 0.3006% | $40.53 | 1 | 25 | |
| Pinion John Richard | See Remarks | 89268 0.091% | $40.53 | 0 | 10 | |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 57981 0.0633% | $40.53 | 0 | 26 | |
| Harris Erik | EVP & Chief Commercial Officer | 67163 0.0625% | $40.53 | 0 | 17 | |
| Crombez Eric | EVP and Chief Medical Officer | 48431 0.0594% | $40.53 | 0 | 3 | |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 41380 0.0288% | $40.53 | 0 | 27 | |
| Fust Matthew K | director | 14860 0.0165% | $40.53 | 1 | 6 | |
| Sanders Corazon (Corsee) D. | director | 7248 0.0109% | $40.53 | 0 | 3 | |
| FMR LLC | 10 percent owner | 3260240 3.9704% | $40.53 | 1 | 0 | +10.41% |
| TPG Group Holdings (SBS) Advisors, Inc. | 2596420 3.162% | $40.53 | 0 | 1 | ||
| Sharp Shalini | EVP, Finance | 97812 0.1191% | $40.53 | 1 | 28 | |
| Huang Dennis Karl | See Remarks | 75314 0.0917% | $40.53 | 0 | 7 | |
| Dier Mardi | CFO & Executive Vice President | 66695 0.0812% | $40.53 | 0 | 5 | |
| Aliski William | director | 65704 0.08% | $40.53 | 1 | 13 | |
| Bedrosian Camille L | EVP and Chief Medical Officer | 46720 0.0569% | $40.53 | 0 | 12 | |
| AGARWAL SUNIL | Chief Medical Officer | 9528 0.0116% | $40.53 | 0 | 12 | |
| SIEGALL CLAY B | director | 2550 0.0031% | $40.53 | 0 | 2 |
Institutional Investor Ownership
| The Vanguard Group | $406.2M | 10.47 | 8.7M | +0.31% | +$1.24M | 0.01 | |
| RTW Investments, LP | $330.9M | 8.53 | 7.09M | +2.9% | +$9.34M | 4.89 | |
| BlackRock | $244.46M | 6.3 | 5.24M | -0.05% | -$124,288.78 | 0.01 | |
| Wellington Management Company | $191.33M | 4.93 | 4.1M | -7.18% | -$14.8M | 0.03 | |
| Sands Capital | $180.2M | 4.64 | 3.86M | -6.28% | -$12.07M | 0.5 | |
| T. Rowe Price | $166.63M | 4.29 | 3.57M | +3.48% | +$5.61M | 0.02 | |
| State Street | $133.12M | 3.43 | 2.85M | -12.34% | -$18.73M | 0.01 | |
| ClearBridge Investments | $112.1M | 2.89 | 2.4M | +0.73% | +$810,631.81 | 0.09 | |
| Alkeon Capital Management Llc | $104.67M | 2.7 | 2.24M | 0% | +$0 | 0.58 | |
| Federated Hermes | $90.52M | 2.33 | 1.94M | -20.76% | -$23.71M | 0.21 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $82.87M | 2.13 | 1.77M | +1.19% | +$975,821.00 | 2.11 | |
| Suvretta Capital Management, LLC | $78.29M | 2.02 | 1.68M | -21.14% | -$20.99M | 3.3 | |
| AllianceBernstein | $69.22M | 1.78 | 1.48M | -6.09% | -$4.49M | 0.02 | |
| Baker Bros Advisors LP | $68.47M | 1.76 | 1.47M | 0% | +$0 | 0.86 | |
| Geode Capital Management | $62.57M | 1.61 | 1.34M | +4.38% | +$2.62M | 0.01 | |
| Deutsche Bank | $56.37M | 1.45 | 1.21M | +2.93% | +$1.6M | 0.03 | |
| Marshall Wace | $45.24M | 1.17 | 968,990 | -34.95% | -$24.3M | 0.06 | |
| Avidity Partners Management Lp | $43.59M | 1.12 | 933,500 | +10.54% | +$4.16M | 1.58 | |
| BNY Mellon | $42.57M | 1.1 | 911,656 | -9.81% | -$4.63M | 0.01 | |
| Avoro Capital Advisors Llc | $38.75M | 1 | 830,000 | +137.14% | +$22.41M | 0.46 | |
| First Light Asset Management | $36.91M | 0.95 | 790,446 | +6.15% | +$2.14M | 2.92 | |
| Fidelity Investments | $36.51M | 0.94 | 782,032 | -21.24% | -$9.85M | <0.01 | |
| Millennium Management LLC | $33.05M | 0.85 | 707,905 | +2,379.35% | +$31.72M | 0.02 | |
| Jacobs Levy Equity Management | $32.1M | 0.83 | 687,619 | -4.36% | -$1.46M | 0.14 | |
| Alger | $27.15M | 0.7 | 581,551 | -3.71% | -$1.05M | 0.14 | |
| Candriam S C A | $24.17M | 0.62 | 517,597 | +248.6% | +$17.23M | 0.16 | |
| Morgan Stanley | $23.55M | 0.61 | 504,382 | -15.59% | -$4.35M | <0.01 | |
| Invesco | $23.48M | 0.61 | 502,852 | +16.94% | +$3.4M | 0.01 | |
| Emerald Advisers, Inc. | $22.79M | 0.59 | 488,138 | +1.24% | +$280,140.00 | 0.93 | |
| Charles Schwab | $22.62M | 0.58 | 484,381 | +2.66% | +$586,239.64 | 0.01 | |
| Two Sigma Advisers LP | $20.93M | 0.54 | 448,200 | +137.27% | +$12.11M | 0.04 | |
| Schonfeld Group | $20.58M | 0.53 | 440,798 | +28.58% | +$4.57M | 0.14 | |
| Bank of America | $20.1M | 0.52 | 430,536 | +25.37% | +$4.07M | <0.01 | |
| Two Sigma | $19.39M | 0.5 | 415,314 | +228.03% | +$13.48M | 0.03 | |
| Woodline Partners LP | $18.68M | 0.48 | 400,124 | 0% | +$0 | 0.18 | |
| Driehaus Capital Management LLC | $18.18M | 0.47 | 389,291 | +8.39% | +$1.41M | 0.18 | |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17.99M | 0.46 | 385,340 | 0% | +$0 | 0.95 | |
| First Trust | $17.19M | 0.44 | 368,219 | -68.34% | -$37.11M | 0.02 | |
| Northern Trust | $17.16M | 0.44 | 367,623 | -1.88% | -$328,604.22 | <0.01 | |
| Goldman Sachs | $17M | 0.44 | 364,122 | +134.84% | +$9.76M | <0.01 | |
| Nuveen | $16.97M | 0.44 | 363,367 | -20.57% | -$4.39M | 0.01 | |
| Eventide Asset Management | $16.76M | 0.43 | 359,000 | 0% | +$0 | 0.26 | |
| AXA | $15.54M | 0.4 | 332,767 | +0.02% | +$2,567.95 | 0.05 | |
| Hudson Bay Capital Management LP | $14.25M | 0.37 | 305,100 | -37.73% | -$8.63M | 0.15 | |
| GW&K Investment Management | $14.16M | 0.37 | 303,377 | -1.35% | -$193,861.37 | 0.13 | |
| Eagle Health Investments Lp | $13.99M | 0.36 | 299,700 | New | +$13.99M | 2.67 | |
| Citadel Advisors LLC | $13.69M | 0.35 | 293,305 | +46.61% | +$4.35M | 0.01 | |
| The Manufacturers Life Insurance Company | $13.42M | 0.35 | 287,504 | +5.57% | +$708,053.86 | 0.01 | |
| Blue Owl Capital Holdings Lp | $12.52M | 0.32 | 268,238 | +1.9% | +$233,450.00 | 2.36 | |
| Massachusetts Financial Services Co Ma | $12.46M | 0.32 | 266,967 | New | +$12.46M | <0.01 |